

Outcomes of the International Medication Safety Network (IMSN) COVID-19 Vaccine Safety Interest Group (CVSIG)

Christina Michalek, BS, RPh, FASHP

Chair, IMSN CVSIG

Medication Safety Specialist, ISMP

International Medication Safety Network (IMSN)

INTERNATIONAL MEDICATION SAFETY NETWORK

HOME ABOUT IMSN IMSN ADVOCACY BEST PRACTICES REPORTING PORTAL PUBLIC EVENTS RESOURCES MEMBERS ONLY

The **International Medication Safety Network (IMSN)** is an international network of established safe medication practice centres, operating medication error reporting programmes and producing guidance to minimise preventable harms from medicine use in practice. IMSN promotes safer medication practice to improve patient safety internationally. [About IMSN](#)

MAIN IMSN EVENTS

Our Covid-19 Vaccine Safety initiative

What is IMSN bringing to you in terms of medication safety?

World Patient Safety Day 17 September 2021

For **World Patient Safety Day, 17 September 2021**, WHO urges all stakeholders to “*Act now for safe and respectful childbirth*” with the theme “*Safe maternal and newborn care*”.

Considering the significant burden of harm women and newborns are exposed to due to unsafe care, this year’s World Patient Safety Day is dedicated to the need to prioritize and address safety in maternal and newborn care, particularly around the time of childbirth, when most harm occurs. This is especially important in the context of disruption of health services due to the COVID-19 pandemic.

Unsafe clinical practices during pregnancy, childbirth and immediately after birth can lead to patient harm.

Health workers must follow safety practices in:

- medication
- blood transfusion
- radiation
- surgery
- medical devices
- sanitation

Prepare and dispense vinca alkaloids in a minibag, never in a syringe

Recent update of the **Global Targeted Medication Safety Best Practice 2** [Read QD...](#)

CVSIG Inception

- *How do PV centers prepare for the authorization of a future COVID-19 vaccine..... 30 October 2020*
- *Does anyone have detailed information with recommendations for preparing the Pfizer vaccine..... 18 December 2020*
- *Important question - preparation of individual doses of Pfizer vaccine..... 31 December 2020*
- 21 January 2021 IMSN Executive Committee proposal

Charter

— Two objectives:

- Address Covid-19 vaccine safety issues by sharing experience and learning from member countries
- Make appropriate recommendations for global implementation
- Timeline: duration of 2021



IMSN Covid-19 Vaccine Safety Interest Group Charter

As the Covid-19 vaccines are being rolled out across the globe, all medication safety and patient safety organizations are concerned about some of the safety issues relating to the operation and the process of vaccination including storage, preparation, administration and patient monitoring of the vaccine. At the global level, acting in real time for sharing and learning from each other will help to maximize the chance of immunization success. The IMSN executive committee has proposed that IMSN takes initiative to develop the **IMSN Covid-19 Vaccine Safety Interest Group** to address these potential issues and stimulate global implementation of safer Covid-19 immunization practices.

Mandates

The two primary objectives of the **IMSN Covid-19 Vaccine Safety Interest Group** are:

1. to address Covid-19 vaccines safety issues and to share the experience and learning from member countries on issues being encountered when challenging the vaccine rollout, therefore offering also to members the opportunity to show what they have done in their own country/organization
2. to make appropriate recommendations for global implementation in order to facilitate implementation of recommendations that are developed by other member countries. The Group may be able to develop a guidance (guiding document) that may be helpful to members and non-members to implement some of the recommendations/actions.

The findings and recommendations will be made publicly available in a specific section of the IMSN website.

Members

The Chair of the **IMSN Covid-19 Vaccine Safety Interest Group** is Christina Michalek, also member COVID-19 team for ECRI and ISMP. The members in this Group will consist of IMSN members on a voluntary basis. The IMSN Chair and the General Secretary will provide input and suggestions as needed.

It is expected both membership from patient safety as well as regulatory agency will participate. Other key stakeholders including WHO, UMC, ISoP and others will be invited to be members of the Group.

Organization & arrangements

Communication and additional information to be shared between the members of the **IMSN Covid-19 Vaccine Safety Interest Group** will be carried out in a specific blog in the IMSN website:

<https://www.intmedsafe.net/forums/topic/covid-19-vaccine/>

The meeting format will be on-line (Zoom or conference call).

Expected timeline: the duration of 2021

Participants

Brazil- Mario Rosa
Borges

Canada- David U,
Dorothy Tscheng,
Gary Lee, Sarah
Finlayson

Health Canada-
Sally Pepper, Jhona
Rose

Columbia- Ismael
Basto, Juan Pablo
Osorio

EMA- Alexis
Skarlatos

France- Marie-
Blanche Rabier,
Etienne Schmitt

Germany- Torsten
Hoppe-Tichy, Birgit
Vogt

Hong Kong-
Benjamin Lee

Ireland- Muriel Pate,
Niamh O'Hanlon

ISoP- Brian
Edwards, Angela
Cora

Morocco- Ghita
Benabdallah, Houda
Sefiani

Netherlands- Jaap
Dik, Rob Essink

New Zealand-
Michael Tatley

Norway – Sigurd
Hortemo

Saudi Arabia- Hind
Almodaimegh

Singapore-
Augustine Tee, Alvin
Lee, Adelina Young
(MOH)

Spain- Maria Jose
Otero

UAE- Sohail Fitieh

UK- Mitul Jadeja
(MHRA), Jennie Hall
(NHS)

UMC – Alem
Zekarias

US- Mike Cohen,
Rita Jew, Jill Paslier,
Merissa Andersen

US FDA – Lubna
Merchant, Karen
Farizo, Craig
Zinderman

US Vaccine
Dynamics – John
Grabenstein

WHO – Ayako
Fukushima, Raffaella
Balocco

Novartis- Matt Fried,
David Yoon

Global Sharing and Learning

Virtual meetings, blog post communication and resource page

Initial country survey


- Available vaccines
- Vaccine roll out process
- Top concerns

Approach to COVID-19 vaccinations –six monthly meetings

- France
- Ireland
- United States
- Canada
- Norway
- Singapore
- New Zealand
- Morocco
- Saudi Arabia
- Uppsala Monitoring Centre
- World Health Organization

Risks and Recommendations

Goal: identify risks, actual errors and address priority recommendations



Recommendations

— Procurement

- Ensure adequate vaccine doses and supplies are available based on the number of people to be vaccinated
- Communicate vaccine delivery timing
- Ensure proper storage conditions for vaccines during transportation and distribution

— Storage

- Plan for appropriate storage of vaccines considering inventory volume, required storage temperature, and transportation needs
- Ensure consistent maintenance of cold chain storage including temperature monitoring of refrigerators and freezers
- Store vaccines in a manner to avoid confusion with other medications or other vaccines
- Segregate vials in use from those that have not been used in storage locations

Recommendations

— Preparation

- Establish a clean, organized area for vaccine preparation
- During preparation follow a workflow that avoids known risks of error and supports early identification of potential errors
- Have a process in place that allows for easy identification of patients who may have received a wrong dose/vaccine/diluent
- When a vaccine requires dilution, apply a label to the vial to indicate that the diluent has been added
- Consider usability studies when distributing multi-dose vials to identify potential issues for leakage during preparation
- Consider usability studies when vaccines are provided in a prefilled syringe that requires assembly prior to administration to identify potential issues with connecting components
- When possible, manufacturers should provide vaccines in a ready-to-administer form
- Apply a label to each dose of vaccine drawn from a multi-dose vial
- When multiple brands of vaccines are in use, restrict to one brand/vaccine type available at a vaccination site
- When training supplies are available at the vaccination sites, restrict them to areas away from where vaccine preparation occurs (e.g., pharmacy areas) to avoid potential confusion with actual vaccines and diluents
- Plan for end of clinic doses to avoid vaccine waste

Recommendations

— Administration

- During appointment booking screen patients for vaccine appropriateness
- When patients arrive to be vaccinated, review vaccine eligibility based on vaccine type/brand, patient age, time/interval between doses, and prior vaccinations
- Ensure the patient flow is clearly marked and communicated, and patients understand how to follow the process from intake/waiting area through vaccination administration and monitoring area
- Educate vaccinators on vaccines to be administered including the approved route of administration, dose(s), risk for SIRVA and how to prevent it, and how to prepare (as required) each dose, including how to use vials, prefilled syringes, and/or syringes and safety needles
- When possible, have different staff prepare and label vaccines from those who will administer vaccines
- Document vaccine administration at the time of administration

Recommendations

— Monitoring and Follow up (short and long term)

- Have medications available in vaccine clinic locations to treat medical emergencies such as an anaphylactic reaction
- When multiple doses are required to achieve immunity, ensure patients are appropriately scheduled to receive subsequent doses
- Educate patients on vaccines, potential adverse effects, and when to seek medical advice
- Communicate with patients to encourage them to complete the vaccination schedule
- Monitor patients for adverse effects beyond the initial monitoring period
- Report adverse events and vaccine errors

Recommendations

— Miscellaneous

- Mis-alignment of regulatory decision making – issues with countries (or within countries) not accepting certain vaccines
- Mixing and matching vaccine brands
- Delays in administration of second dose to promote first doses for more people
- Addressing vaccine hesitancy
- Giving booster doses

Future Efforts

- Pediatric expansion to children 5 – 11 years
 - Vaccine mix-ups predictable
 - Two dose regimen: 10 mcg/0.2 mL (after dilution)
 - Age-dependent formulations
 - Packaging similarities
- Flu season causing an increase in vaccine mix-ups
 - Influenza, COVID boosters, Shingles
 - Possible causes: syringes near each other; unlabeled syringes; distractions; staff shortages; demand to co-administer

Thank You!

cmichalek@ismp.org